Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Portrait de Yi Ping Li
Leeftijd : 56
Vermogen : 37 520 736 USD
Belangrijkste bedrijven : JW (Cayman) Therapeutics Co. Ltd
Overzicht 
Founder of JW Biotechnology (Shanghai) Co. Ltd. and JW Therapeutics (Shanghai) Co., Ltd., Yi Ping Li presently holds the position of Chairman & Chief Executive Officer of JW Therapeutics (Shanghai) Co., Ltd., Chairman & Chief Executive Officer of JW (Cayman) Therapeutics Co. Ltd. and Chief Executive Officer & Director at JW Biotechnology (Shanghai) Co. Ltd. Dr. Li is also on the board of GenScript Corp.

He previously was General Manager of Amgen Biotechnology Consulting Shanghai Co., Ltd., Partner at Kleiner Perkins Caufield & Byers LLC and Partner at KPCB (China) Advisory Co. Ltd. (a subsidiary of Kleiner Perkins Caufield & Byers LLC) and Medical Director at Merck Serono SA.

Dr. Li received a graduate degree from The University of Montana and a doctorate from Shanghai Jiao Tong University.


Posities en verantwoordelijkheden van Yi Ping Li 
NaamTitel Van
JW (Cayman) Therapeutics Co. Ltd
(Biotechnologie & Medisch Onderzoek)
Chairman & Chief Executive Officer 2017
JW Therapeutics (Shanghai) Co., Ltd. Chairman & Chief Executive Officer -
GenScript Corp. Director -
JW Biotechnology (Shanghai) Co. Ltd. Chief Executive Officer & Director -


Belangnemingen van Yi Ping Li 
NaamAandelen%Totale waarde
JW (Cayman) Therapeutics Co. Ltd (2126)
(Biotechnologie & Medisch Onderzoek)
17 685 5304,40%37 520 736 USD


Yi Ping LiPersoonlijk netwerk 
Meest gelezen nieuws 
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Yi Ping Li Verbindingen